Tiny study to reveal how phosphorus in food affects kidneys
NCT ID NCT06712719
First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 3 times
Summary
This study looks at how the amount of phosphorus in food affects phosphorus and calcium balance in people with moderate chronic kidney disease (CKD). Fourteen participants will follow two different controlled diets (low phosphorus then high phosphorus, or vice versa) for 19 days each. Researchers will measure phosphorus and calcium in urine, stool, and blood to understand how the body handles these minerals. The goal is to gather knowledge, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- controlled diets with low or high phosphorus content
- What this could lead to
- If successful, this could help doctors understand how to better manage phosphorus and calcium levels in people with moderate CKD through diet.
- What could go wrong
- This is a very small, early-stage study (14 people) focused on measuring body processes, not testing a treatment. Results may not apply to all CKD patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 14 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
30 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Men or women, ages 30-75 years old, any race or ethnicity * Moderate CKD, defined by KDIGO as eGFR category 3b (30-44 mL/min) or 4 (16-29 mL/min) with albuminuria categories A1-A3 * Serum intact parathyroid hormone above assay normal limit * Female subjects must be postmenopausal (\>12 months since last menstrual period), surgically sterile, or confirmed not pregnant by pregnancy test * Must be on stable doses of medications (except those noted in exclusion criteria) for at least 4 weeks prior to the study * Willing to discontinue supplements (e.g., vitamin D, calcium, multivitamin/minerals, or others) upon enrollment until completion of the study * Adequate vitamin D status defined as serum 25D \> 20 ng/mL based on National Academy of Medicine (then Institute of Medicine) criteria. Exclusion Criteria: * Plans to initiate dialysis within 6 months * Hypercalcemia defined as corrected serum calcium \>9.8 mg/dL within past 3 months * Hyperkalemia defined as serum potassium \>5.5 mg/dL within past 3 months * Hyperphosphatemia defined as serum phosphate \>5.5 mg/dL within past 3 months * Intestinal disease that alters absorption or normal intestinal function including celiac disease, small bowel resection, bariatric surgery, or chronic diarrhea/malabsorption * Serious, uncontrolled underlying systemic disease including diabetes, lupus, hypertension in the opinion of their physician * Pregnant or breastfeeding * Prescribed and taken a phosphate binder medication, calcitriol, vitamin D analogs, calcimimetics, PTH analogues, and other medications that may alter Ca and P metabolism within past 4 weeks * Non-English speaking
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CKD are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Indiana University School of Medicine
Indianapolis, Indiana, 46202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tracking blood markers over time may reveal hidden heart risk
- A simple blood ratio may predict diabetic kidney disease
- A new app maps kidney-friendly meals for dining out in singapore
- Can we predict who will progress quickly to kidney failure?
- Could a triple therapy beat kidney muscle wasting?
- Could a phone app be the key to managing kidney disease?